Madrigal Pharmaceuticals Inc
NASDAQ:MDGL
Intrinsic Value
Madrigal Pharmaceuticals, Inc. engages on the development and commercialization of innovative therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. [ Read More ]
The intrinsic value of one
MDGL
stock under the Base Case scenario is
247.15
USD.
Compared to the current market price of 220.06 USD,
Madrigal Pharmaceuticals Inc
is
Undervalued by 11%.
Madrigal Pharmaceuticals Inc's market capitalization is 4.6B USD.
MDGL stock price is 220.06 USD.
MDGL stock price (220.06 USD) is 11% less than its Intrinsic Value (247.15 USD).
MDGL. Open Relative Valuation
MDGL has upside potential of 75% compared to the average analyst price target.
Open Wall St Estimates
MDGL has negative Free Cash Flow for the last twelve months.
MDGL has negative Operating Income for the last twelve months.
MDGL has negative Net Income for the last twelve months.
MDGL's ROE (Return on Equity) has significantly decreased in the last 3 years from -68% to -89%, and is approaching profitability.
MDGL's ROIC (Return on Invested Capital) has significantly decreased in the last 3 years from 443 400% to 12 095%.
MDGL's ROE (Return on Equity) for the past 12 months is negative and is equal to -89%.
MDGL's ROIC (Return on Invested Capital) for the past 12 months is very high and is equal to 12 095%.
MDGL's D/E (Debt to Equity) is very low and is equal to 0.14.
MDGL has negative three-year average ROE (Return on Equity): -298%. The company is not efficient at transforming stockholders' equity into net income.
MDGL has very high three-year average ROIC (Return on Invested Capital): 36 356%. The company is very efficient at using invested capital to generate operating income.
MDGL's short-term assets (1B USD) exceed its short-term liabilties (114m USD).
MDGL's long-term assets (1B USD) exceed its long-term liabilties (232m USD).
MDGL has negative Net Debt. This means that the company has more cash and short-term investments (1B USD) than debt (116m USD).
MDGL's Altman Z-Score is very high and is equal to 10.9.
Valuation Backtest
Madrigal Pharmaceuticals Inc
Run backtest to discover the historical profit from buying and selling
MDGL
stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Madrigal Pharmaceuticals Inc
Balance Sheet Decomposition
Madrigal Pharmaceuticals Inc
| Current Assets | 1.1B |
| Cash & Short-Term Investments | 1.1B |
| Other Current Assets | 14.9m |
| Non-Current Assets | 8.3m |
| PP&E | 3.3m |
| Intangibles | 5m |
| Current Liabilities | 114.3m |
| Accounts Payable | 21.5m |
| Accrued Liabilities | 92.8m |
| Non-Current Liabilities | 117.2m |
| Long-Term Debt | 116.1m |
| Other Non-Current Liabilities | 1m |
Earnings Waterfall
Madrigal Pharmaceuticals Inc
|
Revenue
|
0
USD
|
|
Operating Expenses
|
-454.2m
USD
|
|
Operating Income
|
-454.2m
USD
|
|
Other Expenses
|
10m
USD
|
|
Net Income
|
-444.2m
USD
|
Free Cash Flow Analysis
Madrigal Pharmaceuticals Inc
MDGL Profitability Score
Profitability Due Diligence
Madrigal Pharmaceuticals Inc's profitability score is 43/100. The higher the profitability score, the more profitable the company is.
Score
Madrigal Pharmaceuticals Inc's profitability score is 43/100. The higher the profitability score, the more profitable the company is.
MDGL Solvency Score
Solvency Due Diligence
Madrigal Pharmaceuticals Inc's solvency score is 87/100. The higher the solvency score, the more solvent the company is.
Score
Madrigal Pharmaceuticals Inc's solvency score is 87/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
MDGL Price Targets Summary
Madrigal Pharmaceuticals Inc
According to Wall Street analysts, the average 1-year price target for
MDGL
is 384.61 USD
with a low forecast of 151.5 USD and a high forecast of 593.25 USD.
Ownership
MDGL Insider Trading
Buy and sell transactions by insiders
| Period | Sold | Bought | Net |
|---|---|---|---|
| 3 Months |
|
|
|
| 6 Months |
|
|
|
| 9 Months |
|
|
|
| 12 Months |
|
|
|
Shareholder Return
MDGL Price
Madrigal Pharmaceuticals Inc
| Average Annual Return | 52.69% |
| Standard Deviation of Annual Returns | 110.61% |
| Max Drawdown | -61% |
| Market Capitalization | 4.5B USD |
| Shares Outstanding | 21 311 500 |
| Percentage of Shares Shorted | 27.13% |
MDGL News
Last Important Events
Madrigal Pharmaceuticals Inc
Significant happenings or occurrences that are of interest to investors. These could be company-specific developments or market-wide shifts.
Sentiment Analysis
Madrigal Pharmaceuticals Inc
Company Profile
Madrigal Pharmaceuticals Inc
Country
Industry
Market Cap
Dividend Yield
Description
Madrigal Pharmaceuticals, Inc. engages on the development and commercialization of innovative therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. The company is headquartered in Conshohocken, Pennsylvania and currently employs 71 full-time employees. The company went IPO on 2007-02-06. The firm is focused on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. The firm's product candidate, resmetirom, is a liver-directed, selective thyroid hormone receptor-ß (THR-ß) agonist developed as a once-daily oral pill to treat a number of disease states, including non-alcoholic steatohepatitis (NASH). NASH is a liver disease that affects people with metabolic diseases, such as obesity and diabetes and non-alcoholic fatty liver disease (NAFLD).
Contact
IPO
Employees
Officers
The intrinsic value of one
MDGL
stock under the Base Case scenario is
247.15
USD.
Compared to the current market price of 220.06 USD,
Madrigal Pharmaceuticals Inc
is
Undervalued by 11%.
You don't have any saved screeners yet
